The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Biocartis; Chrysalis Biomedical Advisors; COMM Santé; Lilly; Pierre Fabre; Sanofi; SERVIER; SERVIER
Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.
 
Zhaohui Jin
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); QED Therapeutics (Inst)
 
Jesse G. Dixon
No Relationships to Disclose
 
Joleen M. Hubbard
Consulting or Advisory Role - Bayer (Inst); BeiGene (Inst); Merck; Taiho Oncology (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); G1 Therapeutics (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Merck (Inst); Pionyr (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Translational Research in Oncology (Inst); Treos Bio (Inst); Trovagene (Inst)
 
Cathy Eng
Consulting or Advisory Role - Bayer Health; Gilead/Forty Seven; GlaxoSmithKline; Hookipa Biotech; Mirati Therapeutics; natera; Pfizer
Research Funding - Elevar Therapeutics; Hutchison China Meditech; Merck; Pfizer
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - HalioDx (Inst); Ipsen (Inst); Pfizer (Inst)
Research Funding - Merck (Inst)
 
Jean-Yves Douillard
No Relationships to Disclose
 
Richard Adams
Honoraria - Amgen; Merck Serono; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER
Speakers' Bureau - Merck Serono
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck Serono; SERVIER
 
Timothy S. Maughan
Employment - AstraZeneca
Consulting or Advisory Role - Pierre Fabre; vertex
Research Funding - Almac Diagnostics (Inst); AstraZeneca (Inst); Merck KgAA (Inst); PsiOxus Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - patent pending
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Alan P. Venook
Consulting or Advisory Role - Amgen; BridgeBio Pharma; Exelixis; GlaxoSmithKline; Merck Sharp & Dohme
Research Funding - Amgen
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Volker Heinemann
Honoraria - Amgen; AstraZeneca; Merck; Pfizer; Pierre Fabre; Roche; Sanofi; SERVIER; Sirtex Medical
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Merck; MSD; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi; Sirtex Medical; TERUMO
Research Funding - Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Servier (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; Roche; SERVIER; Sirtex Medical
 
Sebastian Stintzing
Honoraria - Amgen; Bayer; LEO Pharma; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; Sanofi; Sanofi; SERVIER; Takeda
Research Funding - Merck Serono (Inst); Pierre Fabre (Inst); Roche Molecular Diagnostics (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck KGaA; Pierre Fabre; Roche; Sanofi; Sirtex Medical; Takeda
 
Richard S. Kaplan
Research Funding - AstraZeneca (Inst)
 
Carsten Bokemeyer
Honoraria - AstraZeneca; Bayer; Berlin-Chemie; Bristol-Myers Squibb; Medac; Merck KGaA; Merck Sharp Dohme; Roche; Sanofi
Consulting or Advisory Role - AOK Health Insurance; Bayer Schering Pharma; GSO; Janssen-Cilag GmbH; Merck Sharp & Dohme; Oncology Drug Consult (ODC); Sanofi
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Agile Therapeutics (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Apellis Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BerGenBio (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CPT Cellex Patient Treatment (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Glycostem (Inst); Glycotope GmbH (Inst); immatics (Inst); Incyte (Inst); IO Biotech (Inst); Ipsen (Inst); Isofol Medical (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Millennium (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Servier/Pfizer (Inst); Springworks Therapeutics (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen-Cilag; Merck Serono; Sanofi
 
Benoist Chibaudel
No Relationships to Disclose
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Madrigal Pharmaceuticals; Moderna Therapeutics; Novavax; Opthea; Orphazyme; Twist Bioscience; UniQure; Zogenix
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; Specialised Therapeutics; Targovax
Consulting or Advisory Role - 1Globe Health Institute; Center for Emerging & Neglected Diseases (CEND); Deciphera; FivePHusion; Genor BioPharma; Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Novotech; Revolution Medicines; Specialised Therapeutics; Targovax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); Merck Serono (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme; Sanofi
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Aimery De Gramont
No Relationships to Disclose
 
Qian Shi
Honoraria - Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim; Hoosier Cancer Research Network; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst)